Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Radiological Response and Neutrophil-to-Lymphocyte Ratio as Predictive Factors for Progression-Free and Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib.

Kucharz J, Dumnicka P, Giza A, Demkow U, Kusnierz-Cabala B, Demkow T, Wiechno P.

Adv Exp Med Biol. 2019;1153:31-45. doi: 10.1007/5584_2019_352.

PMID:
30903615
2.

The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.

Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R, Hammers H, Carducci MA.

Eur J Cancer. 2012 Jan;48(2):202-8. doi: 10.1016/j.ejca.2011.09.001. Epub 2011 Oct 19.

3.

Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha.

Dirican A, Kucukzeybek Y, Erten C, Somali I, Demir L, Can A, Payzin KB, Bayoglu IV, Akyol M, Yildiz Y, Koeseoglu M, Alacacioglu A, Tarhan MO.

Asian Pac J Cancer Prev. 2013;14(3):2101-5.

4.
5.

Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.

Pilskog M, Beisland C, Akslen LA, Bostad L, Haug Å, Heinrich D, Hjelle KM, Straume O.

BMC Urol. 2017 Aug 31;17(1):74. doi: 10.1186/s12894-017-0267-6.

6.

Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib.

Thian Y, Gutzeit A, Koh DM, Fisher R, Lote H, Larkin J, Sohaib A.

Radiology. 2014 Nov;273(2):452-61. doi: 10.1148/radiol.14132702. Epub 2014 May 26.

PMID:
24869795
7.

Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.

Keizman D, Sarid D, Lee JL, Sella A, Gottfried M, Hammers H, Eisenberger MA, Carducci MA, Sinibaldi V, Neiman V, Rosenbaum E, Peer A, Neumann A, Mermershtain W, Rouvinov K, Berger R, Yildiz I.

Oncologist. 2016 Oct;21(10):1212-1217. Epub 2016 Jul 5.

8.

Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.

Shi HZ, Tian J, Chen X, Wang D, Li CL.

Clin Genitourin Cancer. 2017 Feb;15(1):139-144. doi: 10.1016/j.clgc.2016.05.007. Epub 2016 May 27.

PMID:
27338518
9.

Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy.

Kobayashi M, Kubo T, Komatsu K, Fujisaki A, Terauchi F, Natsui S, Nukui A, Kurokawa S, Morita T.

Med Oncol. 2013 Jun;30(2):556. doi: 10.1007/s12032-013-0556-1. Epub 2013 Mar 29.

PMID:
23539200
10.

Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib.

Keizman D, Gottfried M, Ish-Shalom M, Maimon N, Peer A, Neumann A, Hammers H, Eisenberger MA, Sinibaldi V, Pili R, Hayat H, Kovel S, Sella A, Boursi B, Weitzen R, Mermershtain W, Rouvinov K, Berger R, Carducci MA.

Oncologist. 2014 Jan;19(1):51-60. doi: 10.1634/theoncologist.2012-0335. Epub 2013 Dec 5.

11.

Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: A single center experience.

Abd Ghafar NK, Alip A, Ong TA, Yap NY, Saad M.

J Cancer Res Ther. 2018 Oct-Dec;14(6):1303-1311. doi: 10.4103/0973-1482.189247.

12.

Prognostic significance of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients treated with selective internal radiation therapy.

D'Emic N, Engelman A, Molitoris J, Hanlon A, Sharma NK, Moeslein FM, Chuong MD.

J Gastrointest Oncol. 2016 Apr;7(2):269-77. doi: 10.3978/j.issn.2078-6891.2015.108.

13.

Sunitinib dose-escalation after disease progression in metastatic renal cell carcinoma.

Raphael J, Thawer A, Bjarnason GA.

Urol Oncol. 2018 Jan;36(1):12.e1-12.e6. doi: 10.1016/j.urolonc.2017.09.004. Epub 2017 Sep 29.

PMID:
28966072
14.

Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma.

Kuzman JA, Stenehjem DD, Merriman J, Agarwal AM, Patel SB, Hahn AW, Alex A, Albertson D, Gill DM, Agarwal N.

BMC Urol. 2017 Jan 5;17(1):1. doi: 10.1186/s12894-016-0192-0.

15.

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.

Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page RD, Beck JT, Cheung F, Yadav S, Patel P, Geoffrois L, Niolat J, Berkowitz N, Marker M, Chen D, Motzer RJ.

Ann Oncol. 2017 Jun 1;28(6):1339-1345. doi: 10.1093/annonc/mdx075. Erratum in: Ann Oncol. 2018 Nov 1;29(11):2269.

16.

Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.

Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton AJ, Früh M.

Lung Cancer. 2017 Sep;111:176-181. doi: 10.1016/j.lungcan.2017.07.024. Epub 2017 Jul 24.

PMID:
28838390
17.

The Role of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Platelets in the Prognosis of Metastatic Renal Cell Carcinoma.

Huszno J, Kolosza Z, Mrochem-Kwarciak J, Rutkowski T, Skladowski K.

Oncology. 2019 May 2:1-11. doi: 10.1159/000498943. [Epub ahead of print]

PMID:
31048577
18.

Prognostic significance of platelet-lymphocyte ratio in patients receiving first-line tyrosine kinase inhibitors for metastatic renal cell cancer.

Park TJ, Cho YH, Chung HS, Hwang EC, Jung SH, Hwang JE, Bae WK, Kim JW, Heo SH, Hur YH, Jung SI, Kwon DD.

Springerplus. 2016 Oct 28;5(1):1889. eCollection 2016.

19.

Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer.

De Giorgi U, Rihawi K, Aieta M, Lo Re G, Sava T, Masini C, Baldazzi V, De Vincenzo F, Camerini A, Fornarini G, Burattini L, Rosti G, Moscetti L, Chiuri VE, Luzi Fedeli S, Ferrari V, Scarpi E, Amadori D, Basso U.

J Geriatr Oncol. 2014 Apr;5(2):156-63. doi: 10.1016/j.jgo.2014.01.001. Epub 2014 Jan 22.

PMID:
24495699
20.

The impact of neutrophil-to-lymphocyte, platelet-to-lymphocyte and haemoglobin-to-platelet ratio on localised renal cell carcinoma oncologic outcomes.

Albisinni S, Pretot D, Al Hajj Obeid W, Aoun F, Quackels T, Peltier A, Roumeguère T.

Prog Urol. 2019 Jun 10. pii: S1166-7087(19)30117-4. doi: 10.1016/j.purol.2019.05.008. [Epub ahead of print]

PMID:
31196826

Supplemental Content

Support Center